Copernicus Therapeutics

Copernicus Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of nucleic acid nanoparticle therapeutics and delivery systems for serious diseases with limited treatment options. The company's proprietary nanotechnology platform enables safe and efficient delivery of DNA, RNA, and short hairpin RNA (shRNA) to... target cells across multiple tissue types, leveraging a mechanism whereby DNA nanoparticles bind to nucleolin, a cell surface protein, to facilitate rapid cellular uptake and nuclear localization without generating toxicities or inflammatory responses. Copernicus' lead program targets cystic fibrosis, a severe genetic lung disorder, with a first-in-class therapeutic candidate that has demonstrated proof-of-concept in a Phase Ib/IIa dose escalation clinical trial. Results from this trial showed that the company's DNA nanoparticles efficiently transferred their gene payload to the nuclei of differentiated airway cells in cystic fibrosis patients, with findings validated and published in peer-reviewed scientific literature. Beyond pulmonary applications, Copernicus' platform technology supports development of additional first-in-class therapies across multiple disease areas and tissue targets, including ocular disorders such as macular degeneration, diabetic retinopathy, glaucoma, and retinitis pigmentosa; neurological conditions including stroke, Parkinson's disease, multiple sclerosis, traumatic brain injury, and Alzheimer's disease; and other pulmonary disorders such as chronic obstructive pulmonary disease, asthma, and viral lung infections. The company has strategically advanced programs in Parkinson's disease and retinitis pigmentosa to demonstrate the versatility and broad applicability of its nuclein-targeting nanoparticle technology across distinct tissue types and disease indications, positioning Copernicus as a leader in the emerging field of nano nucleic acid therapeutics with significant potential to address unmet medical needs across multiple therapeutic ...Read More